LLY
747.85
-0.07%↓
UNH
590.82
-1.04%↓
JNJ
155.2
-0.15%↓
NVO
105.18
+2.52%↑
ABBV
177.14
+3.17%↑
LLY
747.85
-0.07%↓
UNH
590.82
-1.04%↓
JNJ
155.2
-0.15%↓
NVO
105.18
+2.52%↑
ABBV
177.14
+3.17%↑
LLY
747.85
-0.07%↓
UNH
590.82
-1.04%↓
JNJ
155.2
-0.15%↓
NVO
105.18
+2.52%↑
ABBV
177.14
+3.17%↑
LLY
747.85
-0.07%↓
UNH
590.82
-1.04%↓
JNJ
155.2
-0.15%↓
NVO
105.18
+2.52%↑
ABBV
177.14
+3.17%↑
LLY
747.85
-0.07%↓
UNH
590.82
-1.04%↓
JNJ
155.2
-0.15%↓
NVO
105.18
+2.52%↑
ABBV
177.14
+3.17%↑
24h
Current
Min
47.22
Max
47.98
Recommendations | Buy |
---|---|
12 Months Forecast | +40.08 upside |
Next Earnings | 19 Feb 2025 |
---|
By Acuity
50%
50%
162 / 392 Healthcare
By Trading Central
Confidence
Very Strong Bearish Evidence
47.25 / 52.52 Support & Resistance
Past performance is not a reliable indicator of future results.
8 Dec 2023, 20:56 UTC
Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment
DJ
Read
26 Sept 2024, 16:08 UTC
Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com
DJ
Read
26 Sept 2024, 14:20 UTC
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD
DJ
Read
11 Apr 2024, 14:46 UTC
Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com
DJ
Read
8 Dec 2023, 18:45 UTC
FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- 2nd Update
DJ
Read
8 Dec 2023, 16:45 UTC
FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- Update
DJ
Read
8 Dec 2023, 16:21 UTC
FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- WSJ
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 67.07 USD 40.08%
High 100 USD
Low 30 USD
Based on 17 Wall Street analysts offering 12 month price targets forCRISPR Therapeutics AG - Dist in the last 3 months.
By TipRanks
Buy
17 ratings
9
Buy
6
Hold
2
Sell
Based on 17 analysts giving stock ratings to CRISPR Therapeutics AG - Dist in the past 3 months.
By Trading Central
Short Term
Very Strong Bearish Evidence
Recent bearish events outweigh bullish events.
Intermediate Term
Bearish Evidence
Recent bearish events outweigh bullish events.
Long Term
Weak Bearish Evidence
All events are bearish.
By Acuity
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
$